Top

Drugs & Therapy Perspectives

Published in:

01-08-2003 | Drugs and Profile Reports

Leuprolide acetate (once-yearly implant): profile report

Authors: Judd W. Moul, David J. Vaughn

Published in: Drugs & Therapy Perspectives | Issue 8/2003

Excerpt

Adapted and reproduced from Am J Cancer 2003; 2 (1): 57-66 [1‐3] …

The use of a tradename is for product identification purposes only and does not imply endorsement.

Croom KF, Perry CM. Leuprolide acetate: once-yearly subcutaneous implant in advanced prostate cancer. Am J Cancer 2003; 2(1): 57–64CrossRef

Moul JW. Leuprolide acetate: a viewpoint. Am J Cancer 2003; 2(1): 65CrossRef

Vaughn DJ. Leuprolide acetate: a viewpoint. Am J Cancer 2003; 2(1): 65–6CrossRef

Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet 2002; 41(7): 485–504PubMedCrossRef

Plosker GL, Brogden RN. Leuprorelin: a review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. Drugs 1994 Dec; 48: 930–67PubMedCrossRef

Bayer Corporation. Viadur (leuprolide acetate implant) prescribing information. Package insert. USA: Bayer Corporation, 2002

Fowler Jr JE, Gottesman JE, Reid CF, et al. Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. J Urol 2000 Sep; 164(3 Pt 1): 730–4PubMed

Fowler Jr JE, Flanagan M, Gleason DM, et al. Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer. Urology 2000 May; 55: 639–42PubMedCrossRef

Fowler Jr JE. Patient-reported experience with the Viadur 12-month leuprolide implant for prostate cancer. Urology 2001 Sep; 58(3): 430–4PubMedCrossRef

10.

Jeni AB, Hanks G, Asbell S, et al. Changing face and different countenances of prostate cancer: racial and geographic difference in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer 2001; 96(6): 363–71CrossRef

11.

Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000; 163(6): 1632–42PubMedCrossRef

12.

Moul JW. Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy. Mol Urol 2000; 4(3): 267–73PubMed

13.

Moul JW, Civitelli K. Managing advanced prostate cancer with Viadur (leuprolide acetate implant). Urol Nurs 2001 Dec; 21(6): 385–8, 393-4; quiz 395–6PubMed

14.

Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in advanced prostate cancer: a systematic review and meta-analysis. Ann Int Med 2000; 132: 566–77PubMed

15.

SWOG-9346 — Phase III Intergroup. Intermittent androgen deprivation in patients with stage D2 prostate cancer, Phase III [online]. Available from URL: http://swog.org [Accessed 2003 Jan 7]

Title: Leuprolide acetate (once-yearly implant): profile report
Authors: Judd W. Moul
David J. Vaughn
Publication date: 01-08-2003
Publisher: Springer International Publishing
Published in: Drugs & Therapy Perspectives / Issue 8/2003
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI: https://doi.org/10.2165/00042310-200319080-00003

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Leuprolide acetate (once-yearly implant): profile report

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2003

Gender differences in pharmacokinetics can be detected but their clinical relevance remains unclear

New in the marketplace

Early recognition and prompt treatment are essential in the management of the dermatological complications of obesity

The sky’s the limit when exercise-induced bronchoconstriction is managed appropriately

Therapeutic drug monitoring is a useful tool for a sub-set of patients with tuberculosis

Bimatoprost: an effective second-line option in the treatment open-angle glaucoma and ocular hypertension